1. Home
  2. ALT vs PHAT Comparison

ALT vs PHAT Comparison

Compare ALT & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • PHAT
  • Stock Information
  • Founded
  • ALT 1997
  • PHAT 2018
  • Country
  • ALT United States
  • PHAT United States
  • Employees
  • ALT N/A
  • PHAT N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • PHAT Biotechnology: Pharmaceutical Preparations
  • Sector
  • ALT Health Care
  • PHAT Health Care
  • Exchange
  • ALT Nasdaq
  • PHAT Nasdaq
  • Market Cap
  • ALT 472.3M
  • PHAT 465.0M
  • IPO Year
  • ALT N/A
  • PHAT 2019
  • Fundamental
  • Price
  • ALT $6.43
  • PHAT $5.67
  • Analyst Decision
  • ALT Strong Buy
  • PHAT Strong Buy
  • Analyst Count
  • ALT 7
  • PHAT 4
  • Target Price
  • ALT $20.83
  • PHAT $23.00
  • AVG Volume (30 Days)
  • ALT 2.0M
  • PHAT 1.0M
  • Earning Date
  • ALT 02-27-2025
  • PHAT 03-06-2025
  • Dividend Yield
  • ALT N/A
  • PHAT N/A
  • EPS Growth
  • ALT N/A
  • PHAT N/A
  • EPS
  • ALT N/A
  • PHAT N/A
  • Revenue
  • ALT $52,000.00
  • PHAT $26,270,000.00
  • Revenue This Year
  • ALT N/A
  • PHAT $7,453.23
  • Revenue Next Year
  • ALT N/A
  • PHAT $226.38
  • P/E Ratio
  • ALT N/A
  • PHAT N/A
  • Revenue Growth
  • ALT N/A
  • PHAT N/A
  • 52 Week Low
  • ALT $5.28
  • PHAT $5.21
  • 52 Week High
  • ALT $14.84
  • PHAT $19.71
  • Technical
  • Relative Strength Index (RSI)
  • ALT 42.82
  • PHAT 39.59
  • Support Level
  • ALT $6.06
  • PHAT $5.50
  • Resistance Level
  • ALT $7.10
  • PHAT $6.21
  • Average True Range (ATR)
  • ALT 0.36
  • PHAT 0.40
  • MACD
  • ALT 0.03
  • PHAT 0.07
  • Stochastic Oscillator
  • ALT 33.33
  • PHAT 38.69

About ALT Altimmune Inc.

Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: